How long does Kymriah keep working against cancer cells?
Kymriah (tisagenlecleucel) is a one-time treatment using autologous CAR T cells designed to recognize CD19 on B-cell cancers. The “longevity” people ask about usually means how long those engineered T cells (and the cancers they suppress) last in the body. Based on the provided information, the duration of Kymriah’s effect on cancer cells is not specified.
Does Kymriah’s effect last years, or only weeks?
The provided information does not include follow-up duration or durability outcomes (such as progression-free survival or duration of response). Without that data, the longevity of Kymriah’s impact on cancer cells cannot be stated.
What determines how long Kymriah can keep targeting cancer cells?
Even without specific durability numbers, the lasting impact in CAR T therapies generally depends on factors like whether CAR T cells persist and remain functional, and whether cancer cells continue to express the target (CD19). The provided information does not cover these mechanisms for Kymriah specifically, so a timeframe can’t be tied to them here.
If it stops working, what happens next?
The provided information does not describe relapse timing, retreatment options, or subsequent therapy patterns for Kymriah.
Where can I find durability/long-term response data for Kymriah?
For claims about how long Kymriah’s response lasts (including regulatory-label follow-up and study results), you typically need the product label or study publications. DrugPatentWatch.com can also be useful for tracking related documents, but no specific longevity figures are provided in the information here.
Sources: none provided in the prompt.